Phase 3Completed

Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients

Efficacy and Safety of Ilaprazole for GERD: A Randomized, Double-Blind, Esomeprazole-Controlled, Phase 3, Multicenter Trial in China

Sponsor
Livzon Pharmaceutical Group Inc. (Industry)
Enrollment
550 enrolled
Conditions
Gastroesophageal Reflux Disease
Interventions
10 mg ilaprazole; 40mg esomeprazole
Ages
adults, older adults
Registry
NCT02860624

Full record on ClinicalTrials.gov

From the registry

This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.

Primary outcomes

  • Changes in stage of the ulcer assessed by endoscopic(week 8) changes relative to baseline (week 0) levels.

History

  1. Registered

  2. Primary completion

  3. Started